They further demonstrated that the SGLT2 inhibitor, dapagliflozin, plays a crucial role in the regression of left ventricular hypertrophy in patients with T2DM and can lead to reverse remodeling and changes of left ventricular structure [14]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.